35Pharma Announces Clearance of Clinical Trial Application for HS135, Best-in-Class Activin and GDF Inhibitor
Montréal, QC, Canada (Jan 03, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate HS135-001, a Phase 1 study of HS135 in healthy volunteers. “Overactive Activin and GDF signalling is a genetically and clinically validated […]
